Regeneron & Telix Partner for Radiopharmaceuticals; Telix Gets $40M Upfront

Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a collaboration to jointly develop and co-commercialize next-generation radiopharmaceutical therapies. The partnership will operate on a 50/50 cost and profit-sharing model, combining Regeneron's antibody expertise with Telix's radiopharmaceutical capabilities. Telix will receive an initial $40 million upfront for four programs, with potential for up to $2.1 billion in milestones and royalties if it opts out of co-funding for specific programs. This collaboration marks Regeneron's entry into the targeted radiopharmaceuticals space.